Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients-Reference-Cited by-同舟云学术

Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients

Published:2021-05-01 Issue:9-10 Volume:32 Page:481-494
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Ouyang Wenjie¹²³,Dong Guoyi¹²³⁴,Zhao Weihua⁵,Li Jing¹²³⁴,Zhou Ziheng¹²,Yang Gaohui⁶,Liu Rongrong⁶,Li Yue⁷,Zhang Qiaoxia⁵,Du Xin⁵,Sun Haixi¹²,Gu Ying¹²³,Lai Yongrong⁶,Liu Sixi⁷,Liu Chao¹²³

Affiliation:

1. BGI-Shenzhen, Shenzhen, China

2. China National GeneBank, BGI-Shenzhen, Shenzhen, China

3. Guangdong Provincial Key Laboratory of Genome Read and Write, BGI-Shenzhen, Shenzhen, China

4. BGI Education Center, University of Chinese Academy Sciences, Shenzhen, China

5. Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China

6. Department of Hematology, First Affiliated Hospital of Guangxi Medical University, Nanning, China

7. Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/hum.2020.204

Reference54 articles.

1. Global epidemiology of haemoglobin disorders and derived service indicators

2. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates

3. World Distribution, Population Genetics, and Health Burden of the Hemoglobinopathies

4. Ethical considerations on preimplantation genetic diagnosis for HLA typing to match a future child as a donor of haematopoietic stem cells to a sibling

5. Non-endocrine late complications in children after allogeneic haematopoietic SCT

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene therapy using optimized LentiHBB^T87Qvector in two patients with transfusion dependent β-thalassemia;2023-03-27

2. A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America;PharmacoEconomics - Open;2023-02-11

3. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance;Blood Advances;2023-01-27

4. Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance–A retrospective cohort study;PLOS ONE;2022-11-29

5. A landscape analysis and discussion of value of gene therapies for sickle cell disease;Expert Review of Pharmacoeconomics & Outcomes Research;2022-04-18